39.75 USD
-0.91 (-2.24%)
39.88 USD
+0.13 (+0.33%)
Taking everything into account, NUVA scores 4 out of 10 in our fundamental rating. NUVA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of NUVA while its profitability can be described as average. NUVA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year NUVA was profitable.
In the past year NUVA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NUVA reported negative net income in multiple years.
In the past 5 years NUVA always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of NUVA (1.36%) is better than 75.38% of its industry peers.
With a decent Return On Equity value of 3.19%, NUVA is doing good in the industry, outperforming 76.38% of the companies in the same industry.
NUVA has a Return On Invested Capital of 3.43%. This is in the better half of the industry: NUVA outperforms 76.38% of its industry peers.
NUVA had an Average Return On Invested Capital over the past 3 years of 2.87%. This is significantly below the industry average of 8.81%.
The 3 year average ROIC (2.87%) for NUVA is below the current ROIC(3.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 3.19% | ||
| ROIC | 3.43% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
1.3 Margins
With a decent Profit Margin value of 2.32%, NUVA is doing good in the industry, outperforming 74.37% of the companies in the same industry.
NUVA's Profit Margin has declined in the last couple of years.
NUVA has a Operating Margin of 6.73%. This is in the better half of the industry: NUVA outperforms 74.87% of its industry peers.
In the last couple of years the Operating Margin of NUVA has declined.
With an excellent Gross Margin value of 71.66%, NUVA belongs to the best of the industry, outperforming 82.41% of the companies in the same industry.
NUVA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.73% | ||
| PM (TTM) | 2.32% | ||
| GM | 71.66% |
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NUVA is destroying value.
The number of shares outstanding for NUVA has been increased compared to 1 year ago.
NUVA has a better debt/assets ratio than last year.
2.2 Solvency
NUVA has an Altman-Z score of 1.91. This is not the best score and indicates that NUVA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.91, NUVA perfoms like the industry average, outperforming 57.29% of the companies in the same industry.
NUVA has a Debt/Equity ratio of 0.89. This is a neutral value indicating NUVA is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.89, NUVA is doing worse than 78.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.91 |
ROIC/WACC0.42
WACC8.11%
2.3 Liquidity
NUVA has a Current Ratio of 1.25. This is a normal value and indicates that NUVA is financially healthy and should not expect problems in meeting its short term obligations.
NUVA has a Current ratio of 1.25. This is amonst the worse of the industry: NUVA underperforms 89.45% of its industry peers.
NUVA has a Quick Ratio of 1.25. This is a bad value and indicates that NUVA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NUVA (0.65) is worse than 93.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
NUVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.61%, which is quite good.
Measured over the past 5 years, NUVA shows a small growth in Earnings Per Share. The EPS has been growing by 0.62% on average per year.
Looking at the last year, NUVA shows a small growth in Revenue. The Revenue has grown by 4.44% in the last year.
The Revenue has been growing slightly by 3.20% on average over the past years.
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%
3.2 Future
Based on estimates for the next years, NUVA will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.32% on average per year.
The Revenue is expected to grow by 6.89% on average over the next years.
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.88 indicates a rather expensive valuation of NUVA.
Compared to the rest of the industry, the Price/Earnings ratio of NUVA indicates a rather cheap valuation: NUVA is cheaper than 86.93% of the companies listed in the same industry.
NUVA's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.76.
A Price/Forward Earnings ratio of 15.23 indicates a correct valuation of NUVA.
88.44% of the companies in the same industry are more expensive than NUVA, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.96, NUVA is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.88 | ||
| Fwd PE | 15.23 |
4.2 Price Multiples
93.47% of the companies in the same industry are more expensive than NUVA, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NUVA has a very decent profitability rating, which may justify a higher PE ratio.
NUVA's earnings are expected to grow with 14.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.42
PEG (5Y)32.2
EPS Next 2Y14.82%
EPS Next 3Y14.9%
5. Dividend
5.1 Amount
NUVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
39.75
-0.91 (-2.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change0%
Market Cap2.08B
Revenue(TTM)1.23B
Net Income(TTM)28.45M
Analysts70.91
Price Target50.72 (27.6%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.04%
Min EPS beat(2)0.41%
Max EPS beat(2)7.68%
EPS beat(4)2
Avg EPS beat(4)-2.68%
Min EPS beat(4)-17.19%
Max EPS beat(4)7.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.05%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)1.16%
Revenue beat(4)1
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.53%
PT rev (3m)2.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.88 | ||
| Fwd PE | 15.23 | ||
| P/S | 1.7 | ||
| P/FCF | N/A | ||
| P/OCF | 14.94 | ||
| P/B | 2.34 | ||
| P/tB | 24.74 | ||
| EV/EBITDA | 11 |
EPS(TTM)2
EY5.03%
EPS(NY)2.61
Fwd EY6.57%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)2.66
OCFY6.69%
SpS23.38
BVpS17.02
TBVpS1.61
PEG (NY)1.42
PEG (5Y)32.2
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 3.19% | ||
| ROCE | 5.48% | ||
| ROIC | 3.43% | ||
| ROICexc | 3.59% | ||
| ROICexgc | 6.59% | ||
| OM | 6.73% | ||
| PM (TTM) | 2.32% | ||
| GM | 71.66% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
ROICexc(3y)4.12%
ROICexc(5y)4.87%
ROICexgc(3y)17.94%
ROICexgc(5y)16.07%
ROCE(3y)3.71%
ROCE(5y)5.01%
ROICexgc growth 3Y3.59%
ROICexgc growth 5Y-1.31%
ROICexc growth 3Y-7.11%
ROICexc growth 5Y-4.99%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
F-Score7
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.89 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.58 | ||
| Cap/Depr | 101.93% | ||
| Cap/Sales | 11.65% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z | 1.91 |
F-Score7
WACC8.11%
ROIC/WACC0.42
Cap/Depr(3y)82.61%
Cap/Depr(5y)85.69%
Cap/Sales(3y)10.64%
Cap/Sales(5y)10.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%
EBIT growth 1Y45.07%
EBIT growth 3Y-11.68%
EBIT growth 5Y-7.06%
EBIT Next Year96.6%
EBIT Next 3Y33.66%
EBIT Next 5Y25.87%
FCF growth 1Y-102.72%
FCF growth 3Y-34.34%
FCF growth 5Y-14.37%
OCF growth 1Y-39.92%
OCF growth 3Y-10.42%
OCF growth 5Y-0.91%
NUVASIVE INC / NUVA FAQ
What is the fundamental rating for NUVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to NUVA.
What is the valuation status of NUVASIVE INC (NUVA) stock?
ChartMill assigns a valuation rating of 5 / 10 to NUVASIVE INC (NUVA). This can be considered as Fairly Valued.
What is the profitability of NUVA stock?
NUVASIVE INC (NUVA) has a profitability rating of 6 / 10.
What is the earnings growth outlook for NUVASIVE INC?
The Earnings per Share (EPS) of NUVASIVE INC (NUVA) is expected to grow by 13.97% in the next year.